← Back to Home

Making Surviving Retinal Cells Sensitive to Light: Trial in 10 People Shows Limited Visual Improvement

Gene therapy paired with special goggles helped some patients with advanced retinitis pigmentosa better detect light, locate objects, and even find a doorway. But these gains have not restored the ability to read or recognize faces, and practical vision restoration remains some way off.

By SURL BioNews

For people who have lost most of their sight, detecting an object in front of them or finding a room’s exit can be a meaningful change. An early clinical study involving 10 patients with advanced retinitis pigmentosa showed that gene therapy combined with light-stimulating goggles could restore limited visual function in some participants. However, the improvements remained concentrated in detecting light and objects, without restoring normal vision.

The study, conducted by the Institute of Molecular and Clinical Ophthalmology Basel in collaboration with the University of Pittsburgh and other institutions, was published in The New England Journal of Medicine and was part of the GenSight Biologics-supported PIONEER trial (NCT03326336). The team reported partial visual recovery in one patient in 2021. It has now expanded its observations to 10 patients with little or no remaining vision to explore whether the same approach could work in more people.

Retinitis pigmentosa progressively destroys photoreceptor cells. This optogenetic therapy takes another approach: genetic instructions for producing the light-sensitive protein ChrimsonR are injected into the eye with poorer vision, enabling surviving retinal ganglion cells, which normally transmit visual signals, to respond to light as well. A camera on the goggles captures the scene ahead, then converts changes in brightness into pulses of amber light projected onto the treated retina.

According to the University of Pittsburgh’s account, 7 of the 10 participants showed improved light sensitivity, with 6 reaching a level the study described as clinically meaningful. The figure of 6 released by the Basel institute refers to this same, more clearly defined improvement. In tests of everyday function, Science News reported that, among the 8 participants who completed behavioral testing after treatment, 4 could find a doorway or walk along a line while wearing the goggles. However, no participant gained the ability to read text or recognize faces as a result, and increased light sensitivity cannot be directly equated with restored clear vision.

The study also sought to answer whether the new signals received by the eye actually reached the brain. Electroencephalography provided evidence that the visual cortex processed signals from objects. The University of Pittsburgh noted that 4 participants continued to show improvements across multiple functional tasks during testing over periods ranging from months to years. The Basel team also observed that people who trained more with the goggles tended to perform better at object detection. This is evidence of a correlation and does not yet establish how the amount of training affects treatment efficacy.

Safety was the primary focus of assessment in this early study. The research institutions described the results as encouraging, but the treatment was not without side effects: the ocular adverse reactions listed by the University of Pittsburgh were mostly mild or moderate, including temporary inflammation and brief increases in intraocular pressure. Experience in just 10 people is insufficient to rule out rarer or longer-term risks.

This study advances optogenetic vision restoration from a single case to a small group of patients, while also outlining the limits of its applicability: patients need both surviving retinal cells and an optic nerve capable of carrying signals to the brain. Larger studies are needed next to determine which patients can benefit, how long the effects can last, and whether improvements observed in testing can consistently translate into the ability to move around in daily life.

References

  1. Institute of Molecular and Clinical Ophthalmology Basel
  2. University of Pittsburgh School of Medicine
  3. Science News